Alnylam Q2 net product rev $410M +34% YoY; HELIOS-B positive; guidance raised

ALNYLAM PHARMACEUTICALS, INC.

2024-Q2 EPS reported -$0.66 revenue$1,154,158,000

Global net product revenue $410M, up 34% YoY; TTR business (ONPATTRO+AMVUTTRA) grew 37% YoY.
HELIOS-B Phase 3 vutrisiran met primary endpoint (28% reduction composite); all-cause mortality reduced 36% in overall population.
GAAP net loss $16.9M; non-GAAP net income $73.8M ($0.58 non-GAAP diluted EPS).
Raised 2024 combined net product revenue guidance from $1.4-1.5B to $1.575-1.65B.
Planned sNDA submission for vutrisiran using Priority Review Voucher; Phase 3 for ALN-TTRsc04 at year-end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.